Literature DB >> 19021058

Prospective monocentric study of non-tunnelled central venous catheter-related complications in hematological patients.

Anna Maria Nosari1, Guido Nador, Andrea De Gasperi, Giuseppe Ortisi, Alberto Volonterio, Silvia Cantoni, Michele Nichelatti, Laura Marbello, Ernestina Mazza, Valentina Mancini, Erica Ravelli, Francesca Ricci, Denis Ciapanna, Federica Garrone, Giovanni Gesu, Enrica Morra.   

Abstract

Indwelling central venous catheters (CVCs) are used in the management of hematologic patients. However, insertion and maintenance of CVCs are susceptible to complications. Study design and methods data concerning 388 consecutive catheterisations, performed in oncohematologic patients between April 2003 and December 2004, were prospectively collected. At insertion thrombocytopenia was present in 109 cases (28.1%) and neutropenia in 67 (17.3%). Hemorrhage after CVC insertion occurred in five thrombocytopenic patients (1.3%). The median duration of catheterisation was 18.8 days (range 1-89), longer in the 7-French CVCs utilised in leukemic patients (24.3 days) and shorter in 12-French CVCs (11 days), used for PBSC harvesting. Deep venous thrombosis was diagnosed in 13 cases (3.3%). Ninety-two catheterisations (12.6/1000 days-catheter) were complicated by infections: 19 local infections (4.8%) and 73 (18.8%) bacteraemias of which 45 (11.6%) were catheter-related, mainly due to Gram positive germs (32/45, 71.1%). The frequency of catheter-related bacteraemia was 7.2 events/1000 days-catheter. Thirteen CVCs were removed due to thrombosis, 15 due to infections, 20 due to malfunction, the remaining 333 at patients discharge. At univariate analysis high-dose chemotherapy (p = 0.013), 7-Fr lumen (p = 0.023), acute myeloid leukemia (AML) (p = 0.001), duration of neutropenia >10 days and length of catheterisation were significantly correlated to infection. Multivariate analysis confirmed the duration of catheterisation, AML and high-dose chemotherapy as risk factors. Even though hematological in-patients are at increased risk for bleeding and infections, non-tunnelled CVCs offer a safe venous access also in patients affected by severe thrombocytopenia and prolonged neutropenia.

Entities:  

Mesh:

Year:  2008        PMID: 19021058     DOI: 10.1080/10428190802409930

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  4 in total

1.  Safety of central venous catheter placement at diagnosis of acute lymphoblastic leukemia in children.

Authors:  G Gonzalez; A M Davidoff; S C Howard; C-H Pui; B N Rao; J L Shenep; A Wozniak; S J Shochat
Journal:  Pediatr Blood Cancer       Date:  2011-12-11       Impact factor: 3.167

2.  The duration of functioning of a subcutaneous implantable port for the treatment of hematological tumors: a single institution-based study.

Authors:  Hitoshi Ohno; Chisaki Mizumoto; Yoshihiro Otsuki; Shigeru Oguma; Yataro Yoshida
Journal:  Int J Clin Oncol       Date:  2010-03-02       Impact factor: 3.402

3.  Catheter management across patients with hematologic malignancies and catheter-related blood stream infections: a systematic review.

Authors:  Kiyan Heybati; Rena Seeger; Santhosh Thyagu; Joshua Piticaru; Nanki Ahluwalia; Laveena Munshi
Journal:  Ann Hematol       Date:  2022-09-15       Impact factor: 4.030

4.  Incidence, risk factors and healthcare costs of central line-associated nosocomial bloodstream infections in hematologic and oncologic patients.

Authors:  Claas Baier; Lena Linke; Matthias Eder; Frank Schwab; Iris Freya Chaberny; Ralf-Peter Vonberg; Ella Ebadi
Journal:  PLoS One       Date:  2020-01-24       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.